Navigation Links
The future of interventional cardiology presented at TCT 2008
Date:10/7/2008

  • What do data from the latest studies and trials reveal about stents, and the future of interventional cardiology?
  • What are the newest devices and strategies in the field?
  • How are the new generation of stents performing?
  • How is the role of angioplasty evolving?

TCT 2008 is the annual scientific symposium of the Cardiovascular Research Foundation and the most widely respected forum on these important topics.

Media are encouraged to attend and cover TCT, by clicking on http://www.tctconference.com/index.php?option=com_content&view=article&id=190

Press conferences will be held on the following late breaking trials and registries:

TUESDAY, OCTOBER 14, 9:30 A.M.

  • COOL RCN: A Prospective Randomized Trial Examining the Safety and Efficacy of Systemic Hypothermia for the Prevention of Radiocontrast Nephropathy
  • ISAR-Left Main: A Randomized Comparison of Sirolimus-Eluting and Paclitaxel-Eluting Stents in Unprotected Left Main Coronary Artery Disease
  • FAME: A Prospective Randomized Trial of Fractional Flow Reserve Guided Stenting in Patients with Multivessel Coronary Artery Disease
  • ODESSA: A Prospective Randomized Study Using Optical Coherence Tomography to Evaluate Strut Coverage of Sirolimus-Eluting, Paclitaxel-Eluting, and Zotarolimus-Eluting Coronary Stents
  • DECREASE: A Prospective Registry Examining the Safety and Efficacy of Triple Antiplatelet Therapy After Drug-Eluting Stent Implantation
  • SOS: A Prospective Randomized Trial of Paclitaxel-Eluting Stents vs. Bare-Metal Stents in Saphenous Vein Graft Lesions
  • ENDEAVOR IV: Two-Year Follow-Up from a Prospective Randomized Trial Comparing a Zotarolimus-Eluting Stent and a Paclitaxel-Eluting Stent in Patients with Coronary Artery Disease

WEDNESDAY, OCTOBER 15, 9:00 A.M.

  • ZEST-AMI: A Prospective Randomized Comparison of Zotarolimus-Eluting Stents, Sirolimus-Eluting Stents, and Paclitaxel-Eluting Stents in Patients with Acute Myocardial Infarction
  • PREPARE: A Prospective Randomized Trial of Proximal Microcirculatory Protection in Patients with Acute Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention
  • ARNO: A Prospective Randomized Trial Comparison of Bivalirudin and Unfractionated Heparin Plus Protamine in Patients Undergoing Elective Percutaneous Coronary Intervention
  • NAPLES: A Prospective Randomized Trial Comparison of Bivalirudin and Unfractionated Heparin Plus Tirofiban in Patients with Diabetes Mellitus Undergoing Elective Percutaneous Coronary Intervention
  • PROBI VIRI: A Prospective Randomized Trial of an Extended Bivalirudin Infusion in Patients Undergoing Percutaneous Coronary Intervention
  • ASSIST: A Prospective Randomized Trial Evaluating Early Eptifibatide Administration in Patients with Acute Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention After Thienopyridine Loading
  • FATA: A Prospective Randomized Trial of Tirofiban and Abciximab in Patients with Acute Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention
  • HORIZONS-AMI: A Prospective Randomized Trial of Paclitaxel-Eluting Stents vs. Bare-Metal Stents in Patients with Acute ST-Segment Elevation Myocardial Infarction
  • HORIZONS-AMI: A Prospective Randomized Trial of Bivalirudin vs. Unfractionated Heparin Plus Glycoprotein IIb/IIIa Inhibitors in Patients with Acute ST-Segment Elevation Myocardial Infarction: Long-Term Follow-Up and Interaction with Stent Type

THURSDAY, OCTOBER 16, 9:00 A.M.

  • SORT-OUT III: A Prospective Randomized Comparison of Zotarolimus-Eluting Stents and Sirolimus-Eluting Stents in Patients with Coronary Artery Disease
  • BBC ONE: A Prospective Randomized Comparison of a Single Drug-Eluting Stent Provisional Strategy vs. Routine Dual Drug-Eluting Stents for Coronary Bifurcation Lesions
  • ISAR-TEST-2: A Prospective Randomized Trial Comparing Polymer-Free Rapamycin-Eluting and Probucol-Eluting Stents, Polymer-Based Sirolimus-Eluting Stents, and Zotarolimus-Eluting Stents in Patients with Coronary Artery Disease
  • ESTROFA-2: A Large-Scale Registry Examining the Rates of Stent Thrombosis After Implantation of Zotarolimus-Eluting and Everolimus-Eluting Stents in Patients with Coronary Artery Disease
  • EMPIRE: A Multicenter Registry Evaluating Neuroprotection During Carotid Stenting with a Novel Flow Reversal System
  • EPIC: A Multicenter Registry Evaluating Neuroprotection During Carotid Stenting with a Novel Distal Protection Device First in Human Report: Initial Experience with a Stentless and Retrievable Percutaneous Aortic Valve Prosthesis
  • DIVERGE: A Large-Scale Registry Evaluating a Novel Self-Expanding Drug-Eluting Bifurcation Stent: Clinical, Angiographic, and IVUS Results Western Denmark Heart Registry: A Large-Scale Registry Examining the Safety and Efficacy of Zotarolimus-Eluting and Sirolimus-Eluting Stents in Patients with Coronary Artery Disease


'/>"/>

Contact: Judy Romero
jromero@crf.org
212-851-9311
Cardiovascular Research Foundation
Source:Eurekalert

Related medicine news :

1. Plastic Surgery 2008 to Showcase Future of Plastic Surgery Through Groundbreaking Research
2. A look to the future
3. Campaign for Americas Future Co-Director Roger Hickey Available to Discuss the Future of Health Care Under the Obama and McCain Administrations
4. More Older Americans Seeking Online Resources to Plan for Their Future
5. Social Security Disability Can Be Key to Financial Future
6. Florida Hospital Unveils New Details, Name for Childrens Hospital of the Future
7. New Research Study Seeks Improved Quality of Life for People in the Future with Schizophrenia
8. Office of the Future Environment Study
9. Office of the future environment study
10. Plexus Consulting Group Works With a USAID-Funded Project to Help the Private Hospitals Association of Jordan Create a Roadmap for the Future
11. Seeding the future: SNM grants grow molecular imaging and nuclear medicine research
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)... ... June 27, 2016 , ... ... announced its strategic partnership with Connance, a healthcare industry leader providing predictive ... proven, proprietary technology combine to provide health systems, hospitals and ambulatory surgical ...
(Date:6/26/2016)... ... June 26, 2016 , ... Pixel Film Studios Released ProSlice ... "Film editors can give their videos a whole new perspective by using the ... of Pixel Film Studios. , ProSlice Levels contains over 30 Different presets to ...
(Date:6/25/2016)... ... June 25, 2016 , ... Austin residents seeking Mohs surgery services, can now ... and to Dr. Russell Peckham for medical and surgical dermatology. , Dr. Dorsey brings ... The selective fellowship in Mohs Micrographic Surgery completed by Dr. Dorsey was under the ...
(Date:6/25/2016)... ... 25, 2016 , ... Dr. Calvin Johnson has dedicated his ... implemented orthobiologic procedures as a method for treating his patients. The procedure is ... to perform the treatment. Orthobiologics are substances that orthopaedic surgeons use to help ...
(Date:6/24/2016)... ... 24, 2016 , ... June 19, 2016 is World Sickle Cell Observance Day. ... the benefits of holistic treatments, Serenity Recovery Center of Marne, Michigan, has ... , Sickle Cell Disease (SCD) is a disorder of the red blood cells, which ...
Breaking Medicine News(10 mins):
(Date:6/26/2016)... June 27, 2016  VMS Rehab Systems, Inc. ( ... take whatever measures required to build a strong and ... is currently listed on the OTC Markets-pink current trading ... and CEO, "We are seeing an anomaly in market ... not only by the Company, but shareholders and market ...
(Date:6/24/2016)... SOUTH SAN FRANCISCO, Calif. , June 24, ... GBT ), a biopharmaceutical company developing novel ... with significant unmet needs, today announced the closing ... 6,400,000 shares of common stock, at the public ... the shares in the offering were offered by ...
(Date:6/24/2016)... Va. , June 24, 2016 The ... set of recommendations that would allow biopharmaceutical ... (HCEI) with entities that make formulary and coverage decisions, ... the "value" of new medicines. The recommendations ... does not appear on the drug label, a prohibition ...
Breaking Medicine Technology: